SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Aspira Pathlab & Diagnostics Ltd

BSE: 540788 NSE: ISIN: INE500C01017
  |   Sector:  Healthcare   |   Industry:  Hospital & Healthcare Services

Snapshot

Q.1 Which industry/sub-sector does Aspira Pathlab & Diagnostics Ltd belong to?
Aspira Pathlab & Diagnostics Ltd belongs to the Healthcare sector, operating specifically within the Hospital & Healthcare Services segment.
Q.2 Is Aspira Pathlab & Diagnostics Ltd a good quality company?
Aspira Pathlab & Diagnostics Ltd is a quality company, based on a 10 year financial track record.
Q.3 Is Aspira Pathlab & Diagnostics Ltd undervalued or overvalued?
Aspira Pathlab & Diagnostics Ltd appears Fair, as its key valuation ratios are in line with their past averages.
Q.4 Is Aspira Pathlab & Diagnostics Ltd a good buy now?
Aspira Pathlab & Diagnostics Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd revenue growth is 66.7% for FY-2025 , which is above its 5 year CAGR of 21.2% , indicating faster growth.
Q.2 Gross Profit margin of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Gross profit margin which is the profit after deduction of direct costs, is 16.2% for FY-2025 , which is in line with its 5 year median of 16.2% , indicating stable margins.
Q.3 Operating Profit Margin of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 16.17% for FY-2025 , which is in line with its 5 year median of 16.17% indicating stable margins.
Q.4 Net Profit Margin of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Net Profit Margin is 9.42% for FY-2025 , is above with its 5 year median of 9.08%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 16.2 16.2
Operating Profit Margin 16.17 16.17
Net Profit Margin 9.42 9.08
Q.5 Return on Asset of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Return on Asset is 12.86%, which is above its 5 year historical median of 10.58%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Return on equity is 18.54% for FY-2025 , which is in line with its historical median of 18.54%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Return on capital employed is 19.64% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Cash conversion cycle is 29 days, below its historical median of 45 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.37 1.16
ROE 18.54 18.54
ROCE 19.64 19.64
Cash Conversion Cycle 29 days 45 days
Q.9 Debt to Equity ratio of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Debt-to-Equity ratio is 0.10 , which is lower with the industry average of 0.22 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd Debt to cash flow from operations is 0.64 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Aspira Pathlab & Diagnostics Ltd?
Promoters hold 18.39% of the Aspira Pathlab & Diagnostics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Aspira Pathlab & Diagnostics Ltd vs industry peers?
Aspira Pathlab & Diagnostics Ltd revenue CAGR is 21.18% , compared to the industry median CAGR of 1.49% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 22 144
Gross Profit 3.6 8.2
Operating Profit 3.5 8.4
Net Profit 2.1 5
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.37 0.73
ROE 18.54 13.88
ROCE 19.64 17.77
Cash Conversion Cycle (days) 29.29 2

Valuation & price assessment

Q.1 Stock return of Aspira Pathlab & Diagnostics Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 15.8% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - 15.8% 21.8% -9.5%
Q.3 Valuation ratios of Aspira Pathlab & Diagnostics Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 40.86 0.00 79.71
Price to Book 4.66 1.32 3.54
Price to Sales 2.47 2.16 4.37
EV to EBITDA 17.65 15.93 18.04

Check more companies

1. Aster DM Healthcare
2. Global Health
3. Krishna Inst.Medi
4. Dr. Lal Pathlabs
5. Dr. Agarwals Health
6. RainbowChildrenS Med
7. Vijaya Diagnostic
8. Metropolis Health.
9. Park Medi World
10. HealthcareGlobal
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×